PDF preview of The Clinical Trial Disclosure Maturity Model A Framework for Excellence article.

Article 2 in our Maturity Model series

Executive Summary

In today’s complex and highly regulated clinical trial landscape, ensuring robust disclosure and transparency practices is more critical than ever. As stakeholders demand greater access to clinical trial information, organizations must establish strong processes and governance structures to meet these expectations while maintaining compliance and efficiency. This is where the clinical trial disclosure maturity model comes into play.


About the author

Headshot of Thomas Wicks.

Thomas Wicks

Head of Transparency Operations, Citeline

Thomas Wicks is an experienced strategic leader with over 20 years in life sciences. As Head of Transparency Operations at Citeline, he spearheads strategy for TrialScope's industry-leading disclosure solutions. Thomas is an established thought leader, having spoken at over 60 conferences and authored over 40 publications on disclosure requirements and transparency trends. Thomas is motivated by empowering teams to accelerate solutions that honor trial transparency.

Related resources

Magnifying glass pie chart data examination transparency
JUL 09, 2024
ニュース記事
薬事規制関連支援サービス

The Hidden Implications of Clinical Trial Disclosure Noncompliance

Potential fallout from clinical trial disclosure noncompliance goes beyond regulatory penalties; adherence has improved but less so for smaller companies.

Trial Diversity from a Disclosure Perspective
JUN 03, 2024
ニュース記事
薬事規制関連支援サービス

Trial Diversity from a Disclosure Perspective

At Citeline’s TrialScope EXTRA event, this session focused on clinical trial diversity from FDA action plans and the perspective of disclosure compliance.

Why Disclosure Matters Now: Presenting the Maturity Model for Clinical Trial Transparency
SEP 04, 2024
ニュース記事
薬事規制関連支援サービス

Why Disclosure Matters Now: Presenting the Maturity Model for Clinical Trial Transparency

A comprehensive maturity model for clinical trial disclosure and transparency is a strategic assessment tool for biopharmaceutical companies.